Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) was down 8% during trading on Wednesday . The company traded as low as $33.78 and last traded at $33.78. 56,274 shares traded hands during trading, a decline of 78% from the average session volume of 260,032 shares. The stock had previously closed at $36.73.
Analyst Ratings Changes
COAG has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Hemab Therapeutics in a research note on Friday, June 26th. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target on the stock. Evercore assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price objective on the stock. Finally, Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Hemab Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $41.40.
Read Our Latest Report on Hemab Therapeutics
Hemab Therapeutics Stock Performance
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.
Insider Activity
In other news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the acquisition, the insider owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 2,970,541 shares of company stock valued at $55,459,603 over the last three months.
About Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Read More
- Five stocks we like better than Hemab Therapeutics
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
